e-Pharmatimes

Emcure Launches Poviztra: A New Era for Weight Loss in India Emcure Launches Poviztra: Revolutionizing Weight Management in India Published: December 22, 2025 | Pharmaceutical News India In a major milestone for Indian healthcare, Emcure Pharmaceuticals has announced the commercial launch of Poviztra® (Semaglutide). As the first Indian company to exclusively commercialize this blockbuster molecule from Novo Nordisk, Emcure is set to transform the landscape of obesity treatment in the country. The Breakthrough: Poviztra is a once-weekly semaglutide injection specifically indicated for chronic weight management. It offers the same efficacy as global brands but is tailored for the Indian market through Emcure’s extensive reach. Affordable Access to Global Innovation One of the most significant aspects of this launch is the pricing strategy. Emcure has positioned Poviztra as a highly competitive op...

Novo Nordisk Files FDA Application for CagriSema: A New Era in Weight Management Published: December 19, 2025 In a major move to solidify its leadership in the obesity market, Novo Nordisk officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on December 18, 2025 , for CagriSema . CagriSema is a once-weekly injectable fixed-dose combination of two powerful medications: Semaglutide (2.4 mg): The GLP-1 receptor agonist found in Wegovy. Cagrilintide (2.4 mg): A novel long-acting amylin analogue. Key Highlights from the FDA Submission The application is primarily backed by the REDEFINE 1 clinical trial, which involved over 3,400 adults. The results demonstrated superior weight loss compared to using either component alone: Treatment Group Avg. Weight Loss (68 Weeks) CagriSema 22.7% — 23% ...

Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...

Breaking: EMA's CHMP Backs High-Dose Wegovy® (7.2 mg) for Obesity Treatment Breaking: CHMP Recommends Approval of High-Dose Wegovy® (7.2 mg) for Obesity The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of a new, higher dose of Wegovy® (semaglutide 7.2 mg) . This major regulatory milestone brings a more potent option to patients in the European Union, offering the potential for significantly greater weight loss compared to the standard 2.4 mg maintenance dose. Key Takeaways New Dose Strength: 7.2 mg once weekly (previously capped at 2.4 mg). Efficacy: Clinical trials demonstrated an average weight loss of 20.7% . Target Audience: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. Next Step: Final approval from the European Commission is ...

Wegovy® (Semaglutide) Receives Health Canada Approval for MASH Treatment Breaking: Health Canada Authorizes Wegovy® as First Treatment for Non-Cirrhotic MASH In a landmark decision for liver health, Health Canada has granted Notice of Compliance with Conditions (NOC/c) for Wegovy® (semaglutide injection) . This authorization makes it the first and only treatment available in Canada specifically for adults with non-cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) who have moderate to advanced liver fibrosis. This approval marks a significant turning point in the management of liver disease, offering a targeted pharmaceutical option for a condition that previously relied heavily on lifestyle management alone. Key Takeaways First Mover: Wegovy® is the first approved treatment in Canada for MASH. Target Patient: Adults with non-cirrhotic MASH and stage F2 or F3 fibrosis. Clin...

Scientific Breakdown: The "Eggs Cause Cancer" News in India (Dec 2025) The Context: In December 2025, a controversy erupted after a viral video claimed that a specific batch of eggs from a premium Indian brand (Eggoz) contained residues of a banned antibiotic. This led to widespread panic linking eggs to cancer. 1. The Core Scientific Reason: Antibiotic Residues The primary reason for the news is not the egg itself, but a chemical contaminant found during lab testing. The Chemical Involved: The specific compound found is AOZ (3-amino-2-oxazolidinone) . This is a metabolite (a breakdown product) of Nitrofuran antibiotics. Why it is a problem: Nitrofurans are a class of antibiotics that were historically used in poultry to prevent disease and promote growth. However, they are now banned in India (and globally) because they are classified as genotoxic carcinogens . Mechanism: "Genotoxic" ...

Litigation Update: Dr. Reddy's vs. Novo Nordisk (Semaglutide) Litigation Update • December 12, 2025 Delhi High Court Clears Dr. Reddy's for Semaglutide Exports: Refuses Novo Nordisk Stay In a significant development for the Indian pharmaceutical sector, the Delhi High Court (Division Bench) has today refused to stay a Single Judge's order permitting Dr. Reddy’s Laboratories (DRL) to manufacture and export Semaglutide. This ruling comes as a setback for Danish pharma giant Novo Nordisk , the patent holder of the blockbuster drugs Ozempic and Wegovy , which had sought to completely block DRL from manufacturing the drug in India. ⚖️ The Verdict at a Glance The Decision: The Division Bench (Justices C. Hari Shankar & O.P. Shukla) upheld the Single Judge's interim order. The Winner (Today): Dr. Reddy’s Laborator...

Cipla Launches Yurpeak (Tirzepatide) in India A New Era for Weight Management: Cipla Launches 'Yurpeak' in India The pharma giant partners with Eli Lilly to bring the blockbuster drug Tirzepatide to deeper pockets of the Indian market. The fight against Type 2 diabetes and obesity in India just received a major reinforcement. Cipla Limited has officially announced the launch of Yurpeak , a branded version of the breakthrough drug tirzepatide . This launch marks a strategic collaboration with global innovator Eli Lilly, aiming to make this cutting-edge therapy accessible not just in metros, but in Tier-2 and Tier-3 cities across the country. 🚀 Key Launch Highlights Brand Name: Yurpeak® (Tirzepatide) Indications: Chronic weight management (Obesity) and Type 2 Diabetes Mellitus. Format: Available as a pre-filled Kw...

Delhi High Court Ruling: Novo Nordisk vs Sun Pharma on Semaglutide Litigation Update: Novo Nordisk vs Sun Pharma on Semaglutide The Delhi High Court has passed a crucial order in the ongoing patent battle between Danish pharmaceutical giant Novo Nordisk and Indian major Sun Pharma regarding the manufacture and sale of Semaglutide . Key Takeaways from the Order Export Allowed: Sun Pharma has been permitted to manufacture and export Semaglutide to countries where Novo Nordisk does not hold a valid patent. Domestic Sales Barred: The court has restrained Sun Pharma from selling the drug in the Indian market until the expiry of Novo Nordisk's specific patent in March 2026. Undertaking Recorded: Justice Manmeet Pritam Singh Arora recorded Sun Pharma's undertaking that it would not commercialize the product in India during the patent term. Background of the Dispute ...

Sun Pharma vs. Novo Nordisk: Semaglutide Litigation Update (Dec 2025) The Battle for Semaglutide: Novo Nordisk vs. Sun Pharma By Pharma Insights | Updated: December 9, 2025 | Reading Time: 3 Mins The race to capture the lucrative market for Semaglutide generics has intensified in India. As of December 2025, the Delhi High Court is witnessing a flurry of legal activity involving Danish giant Novo Nordisk and Indian generic major Sun Pharmaceutical Industries . 🚨 Key Update (Dec 9, 2025): Novo Nordisk has filed a fresh plea seeking to restrain Sun Pharma from dealing in the Semaglutide compound. 1. The Core Dispute At the heart of this litigation is Indian Patent No. 262697 . Novo Nordisk, the innovator behind Ozempic and Wegovy, is seeking a permanent injunction to prevent Sun Pharma from manufacturing, selling, or exporting the active p...

The Ozempic Era: The Science & Future of GLP-1 Agonists PharmaTrends Daily Home Health News Reviews Contact Medical Breakthroughs The "Ozempic Era": How GLP-1 Drugs Are Reshaping Health, Hype, and the Future It’s the topic dominating dinner conversations, social media feeds, and financial news alike. You can’t open a news tab without seeing headlines about Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro). We are witnessing a rare moment in pharmaceutical history: a class of drugs, originally designed for Type 2 diabetes, has crossed over to become a cultural phenomenon in weight management. But beyond the headlines, a significant shift in medical science is occurring. The new paradigm: Balancing pharmacological breakthroughs with lifesty...

The Era of Metabolic Health: Top Tools, Trends & Treatments for 2025 The Era of "Metabolic Health": Top Tools, Trends & Treatments for 2025 Updated: December 2025 | Category: Health Tech & Longevity [AD SPACE: Top Banner Ad] For decades, the wellness industry has been obsessed with one metric: the number on the scale. But as we move deeper into 2025, a massive financial and medical shift is occurring. We are officially entering The Era of Metabolic Health . This isn't just about diet trends. It is about a booming market of wearable technology, specialized supplements, and medical interventions designed to optimize your blood sugar and insulin levels. If you are looking to invest in your longevity (or your portfolio), understanding the difference between "weight loss" and "metabolic efficiency" is crucial. Here is the ultimate guide...

Detailed Analysis: Dr. Reddy’s vs. Novo Nordisk - The Semaglutide Verdict Judgment Day: The Semaglutide Verdict Dr. Reddy’s Laboratories Ltd. vs. Novo Nordisk A/S Case Snapshot Case Number CS(COMM) 565/2025 Court Delhi High Court Judge Justice Manmeet Pritam Singh Arora Date of Decision December 2, 2025 Subject Patent Infringement (Semaglutide) Introduction In a high-stakes legal battle that has captivated the pharmaceutical industry, the Delhi H...